수풍순기환 투여가 고지방, 고탄수화물 식이로 유발된 비만형 제2형 당뇨병 동물모델에 미치는 영향
The Effects of Supungsunki-hwan on High Fat, High Carbohydrate Diet-induced Obese Type 2 Diabetic Mouse Model
2
조회
0
다운로드
11
인용
0
참고문헌
키워드
초록
Objective : Obesity is an important cause of diabetes, and lipotoxicity causes insulin resistance. Recently a lot of research is being done on PPAR-α, TNF-α, adiponectin, and leptin, which are important obesity related factors. In this study, we investigated the effects of Supungsunki-hwan on high fat, high carbohydrate diet-induced obese type 2 diabetic mouse models. Methods : Diabetes was induced in ICR male mouse (30±5g) with Surwit's high fat, high sucrose diet. Mice were divided into 4 groups(n=10) of Normal, Control, Supungsunki-hwan group, and acarbose group. The Supungsunki-hwan group was given 10% Supungsunki-hwan in their diet, and the acarbose group was given 0.5% acarbose in their diet. After 6 weeks, body weight, food intake, FBS and OGTT, lipid profile and liver enzymes, epididymal fat weight, and gene expression of leptin, adiponectin, TNF-α and PPAR-α were measured. Leptin, adiponectin, tumor necrosis factor(TNF)-α and peroxisome proliferator-activated receptor (PPAR)-α were evaluated by reverse transcription-polymerase chain reaction. Results : Supungsunki-hwan increased the gene expression of PPAR-α, which reduces lipotoxicity and insulin resistance. Supungsunki-hwan also significantly reduced triglyceride, AST, ALT serum levels, and 1 hour oral glucose tolerance levels. Conclusion : These results show that Supungsunki-hwan improves insulin resistance in the liver and muscles, by reducing triglyceride levels and lipotoxicity through increased PPAR-α gene expression. This is supported by the fact that Supungsunki-hwan significantly reduces 1 hour oral glucose tolerance levels. Therefore we suggest that Supungsunki-hwan would be an effective treatment for obese type 2 diabetic patients.
Abstract
Objective : Obesity is an important cause of diabetes, and lipotoxicity causes insulin resistance. Recently a lot of research is being done on PPAR-α, TNF-α, adiponectin, and leptin, which are important obesity related factors. In this study, we investigated the effects of Supungsunki-hwan on high fat, high carbohydrate diet-induced obese type 2 diabetic mouse models. Methods : Diabetes was induced in ICR male mouse (30±5g) with Surwit's high fat, high sucrose diet. Mice were divided into 4 groups(n=10) of Normal, Control, Supungsunki-hwan group, and acarbose group. The Supungsunki-hwan group was given 10% Supungsunki-hwan in their diet, and the acarbose group was given 0.5% acarbose in their diet. After 6 weeks, body weight, food intake, FBS and OGTT, lipid profile and liver enzymes, epididymal fat weight, and gene expression of leptin, adiponectin, TNF-α and PPAR-α were measured. Leptin, adiponectin, tumor necrosis factor(TNF)-α and peroxisome proliferator-activated receptor (PPAR)-α were evaluated by reverse transcription-polymerase chain reaction. Results : Supungsunki-hwan increased the gene expression of PPAR-α, which reduces lipotoxicity and insulin resistance. Supungsunki-hwan also significantly reduced triglyceride, AST, ALT serum levels, and 1 hour oral glucose tolerance levels. Conclusion : These results show that Supungsunki-hwan improves insulin resistance in the liver and muscles, by reducing triglyceride levels and lipotoxicity through increased PPAR-α gene expression. This is supported by the fact that Supungsunki-hwan significantly reduces 1 hour oral glucose tolerance levels. Therefore we suggest that Supungsunki-hwan would be an effective treatment for obese type 2 diabetic patients.
참고문헌 (27)
- 대한당뇨병학회, "픽업의 핵심 당뇨병학", pp.2~4 (2006), E PUBLIC
- 안영민, "한방으로 이겨내는 당뇨병", pp.14~16 (2003), 홍신문화사
- Centers for Disease Control and Prevention (CDC), "Prevalence of overweight and obesity among adults with diagnosed diabetes-united states, 1988-1994 and 1999-2002", MMWR Morb Mortal Wkly Rep, 53(45), pp.1066~1068 (2004)
- wartz MS, "Type 2 diabetes mellitus in childhood: Obesity and insulin resistance", J Am Osteopath Assoc, 108(9), pp.518~524 (2008)
- Ioannidis I, "The road from obesity to type 2 diabetes", Angiology, 59(2), pp.39S~43S (2008)
- Trayhurn P, "Adipokines: Inflammation and the pleiotropic role of white adipose tissue", Br J Nutr, 92(3), pp.347~355 (2004)
- Javor ED, "Long-term efficacy of leptin replacement in patients with generalized lipodystrophy", Diabetes, 54(7), pp.1994~2002 (2005)
- Korner A, "New predictors of the metabolic syndrome in children-role of adipocytokines", Pediatr Res, 61(6), pp.640~645 (2007)
- 김두만, "Adiponectin과 혈관질환", Biowave, 8(11) (2006)
- 이문규, "Peroxisome Proliferator-Activated Receptor-α (PPAR-α)와 죽상경화증", Biowave, 8(17) (2006)
- Bastard JP, "Recent advances in the relationship between obesity, inflammation, and insulin resistance", Eur Cytokine Netw, 17(1), pp.4~12 (2006)
- Lefebvre P, "Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis", J Clin Invest, 116(3), pp.571~580 (2006)
- 권건혁, "편집 황제내경", pp.77~ (2000), 도서출판 반룡
- 이천, "편주의학입문", 남산당
- 허준, "편집 동의보감", pp.210~, 도서출판 반룡
- 이병철, "수풍순기환이 내당능장애 환자와 경증 당뇨병환자의 혈당조절에 미치는 영향", 대한반방내과학회지, 22(3), pp.285~290 (2001)
- 이성현, "db", db 마우스에서 수풍순기환의 혈당강하 활성 및 기전연구, 1999, pp.7, 335~341
- 배미라, "고지방식이 섭취 마우스에서 수풍순기환과 분할처방들의 혈당강하활성 및 기전", 마우스에서, 28, pp.101~108 (2000)
- Bays H, "Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach", J Clin Endocrinol Metab, 89(2), pp.463~478 (2004)
- Glass CK, "Going nuclear in metabolic and cardiovascular disease", J Clin Invest, 116(3), pp.556~560 (2006)
- Haluzik MM, "PPAR-alpha and insulin sensitivity", Physiol Res, 55(2), pp.115~122 (2006)
- Tsuchida A, "Peroxisome proliferator -activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: Comparison of activation of PPARalpha, PPARgamma, and their combination", Diabetes, 54(12), pp.3358~3370 (2005)
- Ziouzenkova O, "Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: Evidence for an antiinflammatory role for lipoprotein lipase", Proc Natl Acad Sci U S A, 100(5), pp.2730~2735 (2003)
- Tack CJ, "Thiazolidinedione derivatives in type 2 diabetes mellitus", Neth J Med, 64(6), pp.166~174 (2006)
- Scarpello JH, "Metformin therapy and clinical uses", Diab Vasc Dis Res, 5(3), pp.157~167 (2008)
- Hanefeld M, "Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes", Cardiovasc Diabetol, 6, pp.20~ (2007)
- Winzell MS, "The high-fat diet-fed mouse: A model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes", Diabetes, 53(3), pp.S215~S219 (2004)